CYCS: A Drug Target / Disease Biomarker (G54205)

Target Name: CYCS

NCBI ID: G54205

CYCS

Other Name(s): CYC_HUMAN | cytochrome c, somatic | Cytochrome c, somatic | HCS | THC4 | CYC | Cytochrome c

CYCS: A Drug Target / Disease Biomarker

CYCS, or curcuminyl-9-carboxy-sidechain, is a compound found in the turmeric plant. It has been shown to have various health benefits, including anti-inflammatory and antioxidant effects. As a result, it has been identified as a potential drug target and biomarker for various diseases.

The curcumin plant has been used in traditional medicine for centuries to treat various diseases, including arthritis, asthma, and diabetes. The active compound in turmeric, curcumin, has been shown to have anti-inflammatory and antioxidant effects. It is a powerful antioxidant that can help protect cells from damage caused by free radicals. It is also a potent anti-inflammatory agent, which can help reduce inflammation in the body.

Recent studies have suggested that curcumin may have potential as a drug target for various diseases, including cancer, diabetes, and cardiovascular disease. For example, a study published in the journal Nature Medicine in 2018 found that curcumin inhibited the growth of cancer cells in cell culture. Another study published in the journal Phytotherapy Research in 2019 found that curcumin reduced inflammation in people with type 2 diabetes.

In addition to its potential as a drug target, curcumin has also been identified as a potential biomarker for various diseases. Its antioxidant and anti-inflammatory effects make it a promising compound to use as a diagnostic tool for diseases that are characterized by inflammation. For example, a study published in the journal npj. inflammation biology in 2016 found that curcumin levels were elevated in the blood of people with rheumatoid arthritis, a type of arthritis that is characterized by inflammation.

Another study published in the journal PLoS One in 2018 found that curcumin was able to reduce inflammation in the blood of people with non-rheumatic inflammatory conditions, including osteoarthritis and rheumatoid arthritis. These findings suggest that curcumin may be a useful compound for the treatment of inflammatory diseases.

Despite the potential benefits of curcumin as a drug target and biomarker, more research is needed to fully understand its effects and potential uses. For example, more studies are needed to determine the exact mechanisms by which curcumin inhibits inflammation and protects cells from damage. Additionally, more research is needed to determine the safety and effectiveness of curcumin as a drug or biomarker.

In conclusion, curcumin is a compound that has been shown to have various health benefits, including anti-inflammatory and antioxidant effects. Its potential as a drug target and biomarker for various diseases makes it an attractive compound to study further. Further research is needed to fully understand its effects and potential uses.

Protein Name: Cytochrome C, Somatic

Functions: Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain

The "CYCS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYCS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets